Test Code: CBL

BCR-ABL Fusion Gene Screening

Test Methodology:

This test is intended to monitor deep molecular response in patients diagnosed with chronic phase Philadelphia chromosome positive (Ph+) p210 chronic myeloid leukemia (CML) by realtime PCR. It is calibrated against the World Health Organization (WHO) International Genetic Reference Panel. This assay exploits the qPCR double-dye oligonucleotide hydrolysis principle.

Specimen Required: 

6ml EDTA Blood

Turnaround Time : 

Maximum to 5 days